1. Home
  2. PVLA
  3. PVLA News

Latest Palvella Therapeutics Inc. Common Stock (PVLA) News on June 2, 2025

Palvella Therapeutics Strengthens Executive Leadership Team with Appointment of Rare Disease Commercial Veteran Ashley Kline as Chief Commercial Officer
PVLA

GlobeNewswire

6 days ago

Palvella Therapeutics Strengthens Executive Leadership Team with Appointment of Rare Disease Commercial Veteran Ashley Kline as Chief Commercial Officer

PVLA

GuruFocus.com

17 days ago

Palvella Therapeutics Inc (PVLA) Q1 2025 Earnings Call Highlights: Strong Clinical Progress ...

Palvella Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
PVLA

GlobeNewswire

18 days ago

Palvella Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Palvella Therapeutics to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025
PVLA

GlobeNewswire

25 days ago

Palvella Therapeutics to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025

Palvella Therapeutics to Ring the Nasdaq Opening Bell on May 12, 2025
PVLA

GlobeNewswire

a month ago

Palvella Therapeutics to Ring the Nasdaq Opening Bell on May 12, 2025

Why Palvella Therapeutics, Inc. (PVLA) is Surging in 2025
PVLA

Insider Monkey

a month ago

Why Palvella Therapeutics, Inc. (PVLA) is Surging in 2025

One Palvella Therapeutics Insider Raised Their Stake In The Previous Year
PVLA

Simply Wall St.

a month ago

One Palvella Therapeutics Insider Raised Their Stake In The Previous Year

Palvella Therapeutics Announces Abstract Highlighting the Estimated Diagnosed Prevalence and Annual Incidence of Lymphatic Malformations in the U.S. Accepted for Poster Presentation at the 82nd Annual Meeting of the Society for Investigative Dermatology
PVLA

GlobeNewswire

a month ago

Palvella Therapeutics Announces Abstract Highlighting the Estimated Diagnosed Prevalence and Annual Incidence of Lymphatic Malformations in the U.S. Accepted for Poster Presentation at the 82nd Annual Meeting of the Society for Investigative Dermatology

Palvella Therapeutics Granted Additional U.S. Patent for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
PVLA

GlobeNewswire

a month ago

Palvella Therapeutics Granted Additional U.S. Patent for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations

Palvella Therapeutics Announces QTORIN™ Rapamycin 3.9% Anhydrous Gel for the Treatment of Microcystic Lymphatic Malformations Featured in Oral Presentation by Amy Paller, M.S., M.D., Chair of Dermatology at Northwestern University’s Feinberg School of Medicine, at the 15th World Congress of Pediatric Dermatology
PVLA

GlobeNewswire

2 months ago

Palvella Therapeutics Announces QTORIN™ Rapamycin 3.9% Anhydrous Gel for the Treatment of Microcystic Lymphatic Malformations Featured in Oral Presentation by Amy Paller, M.S., M.D., Chair of Dermatology at Northwestern University’s Feinberg School of Medicine, at the 15th World Congress of Pediatric Dermatology

Palvella Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference
PVLA

GlobeNewswire

2 months ago

Palvella Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference

Palvella Therapeutics Announces Late-Breaking Oral Presentation at the 15th World Congress of Pediatric Dermatology
PVLA

GlobeNewswire

2 months ago

Palvella Therapeutics Announces Late-Breaking Oral Presentation at the 15th World Congress of Pediatric Dermatology

PVLA

GuruFocus.com

2 months ago

Palvella Therapeutics Inc (PVLA) Q4 2024 Earnings Call Highlights: Navigating Financial ...

Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update
PVLA

GlobeNewswire

2 months ago

Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update

Palvella Therapeutics to Host Full Year 2024 Financial Results Conference Call on March 31, 2025
PVLA

GlobeNewswire

2 months ago

Palvella Therapeutics to Host Full Year 2024 Financial Results Conference Call on March 31, 2025

Individual investors who hold 41% of Palvella Therapeutics, Inc. (NASDAQ:PVLA) gained 12%, insiders profited as well
PVLA

Simply Wall St.

3 months ago

Individual investors who hold 41% of Palvella Therapeutics, Inc. (NASDAQ:PVLA) gained 12%, insiders profited as well

Why Palvella Therapeutics, Inc. (PVLA) is Skyrocketing So Far in 2025
PVLA

Insider Monkey

3 months ago

Why Palvella Therapeutics, Inc. (PVLA) is Skyrocketing So Far in 2025

Palvella Therapeutics to Present at the TD Cowen 45th Annual Healthcare Conference
PVLA

GlobeNewswire

3 months ago

Palvella Therapeutics to Present at the TD Cowen 45th Annual Healthcare Conference

Palantir initiated, Roku upgraded: Wall Street’s top analyst calls
PVLA

TipRanks

3 months ago

Palantir initiated, Roku upgraded: Wall Street’s top analyst calls

Palvella Therapeutics to Expand Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations to Include the Younger Pediatric Population, Children 3 to 5 Years Old
PVLA

GlobeNewswire

4 months ago

Palvella Therapeutics to Expand Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations to Include the Younger Pediatric Population, Children 3 to 5 Years Old

Palvella Therapeutics Announces Publication of Results from Phase 2 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations in the Journal of Vascular Anomalies
PVLA

GlobeNewswire

5 months ago

Palvella Therapeutics Announces Publication of Results from Phase 2 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations in the Journal of Vascular Anomalies

Palvella Therapeutics Announces First Patients Dosed in Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations
PVLA

GlobeNewswire

5 months ago

Palvella Therapeutics Announces First Patients Dosed in Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations

Palvella Therapeutics initiated with a Buy at H.C. Wainwright
PVLA

TipRanks

5 months ago

Palvella Therapeutics initiated with a Buy at H.C. Wainwright

Share on Social Networks: